Pro- Dopamine Regulator (Synaptamine™) Ends Life Long Terrifying Lucid Dreams in PTSD/ADHD Patients up to One-Year After Intake

A paper just published today in the peer review open access journal Reward Deficiency Syndrome & Addiction Science, revealed that very terrifying life long-lucid dreams in patients with PTSD/ADHD and opiate addiction found relief of these unwanted and sleep disturbing nightmares.  

About 3.6 percent of U.S. adults aged 18 to 54 (5.2 million people) have PTSD during the course of a given year. ADHD is diagnosed approximately three times more in boys than in girls. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. Currently, addiction affects 23.2 million Americans — of whom only about 10 percent are receiving the treatment they need. Importantly, of those with PTSD, 71% to 96% may have nightmares. Moreover, Nightmare disorder affects 11 percent of children with ADHD and lifetime nightmare disorder affects 23 percent, versus 5 and 16 percent of controls.

In a case series non-controlled pilot study led by Thomas McLaughlin, MD, PhD from the Center for Psychiatric Medicine, North Andover, Massachusetts along with nine other qualified authors representing a number of psychiatry departments in prestigious Universities , provided clear evidence that a well-researched Pro-dopamine regulator KB220Z (Synaptamine™) associated with protracted alleviation of terrifying lucid dreams in four patients studied. Previously, the same group published two peer reviewed articles showing complete elimination of these nightmares. Now a total of thirteen of their patients show this dramatic effect translating to a 92% success rate. However, the most exciting finding to date is that in the current case study the authors have surprisingly found a one-year protracted elimination of these lifelong -terrifying  lucid- nightmares up to one –year after stopping KB220z. The authors raise the question of the possibility of neuroplasticity induced changes in the brain-reward circuitry.

To help answer this important but perplexing question, along with Marcelo Febo, PhD Assistant Professor of the department of Psychiatry, University of Florida School of Medicine, acute fMRI experiments were utilized in naïve rodents. It was then revealed compared to placebo that 5 to 15 minutes following oral administration of KB220Z (at an equivalent human dose) resulted in an increased connectivity volume (increased recruitment of neurons firing) following seeding the dorsal hippocampus in select brain regions of the basal ganglia, dorsomedial, globus pallidus, pre-limbic, and ventromedial striatum but not the pre-frontal cortex. These regions are important and activated in lucid dreams while the latter region is not suggesting selectivity. Certainly, rodent experiments do not tell us anything about human dreaming but may help us  understand in-part the possibility of central nervous system neuro-adaptations.

Thomas McLauglin excited about these findings albeit in a small number of a patients stated:

I have tried many treatments including the standard including Prozasin with little to no effects but our recent findings with KB220z provides the possibility of protracted alleviation of terrifying lucid nightmares giving back a patients ability to sleep without fear- what a gift!”

Kenneth Blum, PhD the corresponding author of the paper and inventor of KB220z stated the following:

“It is noteworthy that following many years of basic (animal) and clinical research (human) involving over 30 published studies including neuroimaging reports, showing many benefits of KB220 variants, this complex which we believe balances the glutaminergic-dopaminergic pathways to induce required “dopamine homeostasis” should not be ignored and warrants intensive investigation.”

In spite of the small number of patients it is plausible that this natural complex may provide real promise for millions suffering from nightmares induced by trauma whether military or civic and this work needs to be encouraged for the future potential of the elimination of these terrifying life-long unpleasant dreams and the reestablishment of a pleasant night sleep so well-deserved for all. 

You can find the entire research paper titled: KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams here:

For more information on KB220Z/Synaptamine™ please visit:

Doctor Blum is available for interviews on a limited basis. To book an interview or for more information please contact:

Joe Ullrich, Omni Publicity And Public Relations Group

Media Contact
Company Name: Omni Publicity
Contact Person: Joe Ullrich
Phone: 813-944-3024
City: San Francisco
State: California
Country: United States